Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Capital Expenditures (2020 - 2024)

Immuneering (IMRX) has 5 years of Capital Expenditures data on record, last reported at $9356.0 in Q4 2024.

  • For Q4 2024, Capital Expenditures fell 94.53% year-over-year to $9356.0; the TTM value through Dec 2024 reached $84875.0, down 75.24%, while the annual FY2024 figure was $84875.0, 75.24% down from the prior year.
  • Capital Expenditures reached $9356.0 in Q4 2024 per IMRX's latest filing, up from $5268.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $393134.0 in Q3 2022 and bottomed at $5268.0 in Q3 2024.
  • Average Capital Expenditures over 5 years is $70808.4, with a median of $35125.5 recorded in 2024.
  • Peak YoY movement for Capital Expenditures: skyrocketed 3364.96% in 2022, then tumbled 94.53% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $38058.0 in 2020, then crashed by 65.7% to $13052.0 in 2021, then skyrocketed by 430.97% to $69302.0 in 2022, then skyrocketed by 146.63% to $170918.0 in 2023, then crashed by 94.53% to $9356.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $9356.0 in Q4 2024, $5268.0 in Q3 2024, and $32773.0 in Q2 2024.